Some Antipsychotics May Be Tied to Increased Type 2 Diabetes Risk. (Medical Claims Records)

Article excerpt

Olanzapine, clozapine, and some conventional antipsychotics were associated with an increased risk of newly diagnosed or exacerbations of type 2 diabetes in a study that analyzed several thousand medical claims records of patients with psychosis, Frank D. Gianfrancesco, Ph.D., and his colleagues said.

But risperidone (Risperdal) was associated with a risk that was similar to that of untreated patients in the retrospective study, which was supported by Janssen Pharmaceutica Inc., the manufacturer of risperidone (J. Clin. Psychiatry 63[10]:920-30, 2002).

The study analyzed claims data from two medical plans and measured the onset or exacerbations of type 2 diabetes in 4,308 patients who were treated with different antipsychotics for at least 60 days between April 1996 and December 1997, compared with 3,625 patients with psychosis who were not treated with an antipsychotic during the same period of time.

Those patients who had preexisting type 2 diabetes up to 8 months before the observation period were excluded in an effort to increase the certainty that the population does not have preexisting diabetes, they said, noting that the odds ratios, therefore, "are more accurate indicators of antipsychotic diabetic effects."

The investigators estimated the odds ratio of type 2 diabetes with exposure to each of five antipsychotic drug categories, compared with no treatment, over 12 months of treatment. …


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.